Article

Vascular endothelial growth factor-A promotes Vaccinia virus entry into host cells via activation of the Akt pathway.

Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London. Charterhouse Square, London EC1M 6BQ. United Kingdom.
Journal of Virology (Impact Factor: 4.65). 12/2012; DOI: 10.1128/JVI.00854-12
Source: PubMed

ABSTRACT Vaccinia virus (VV) is an enveloped DNA virus from the poxvirus family and has played a crucial role in the eradication of smallpox. It continues to be used in immunotherapy for prevention of infectious diseases and treatment of cancer. However, the mechanisms of poxvirus entry, the host factors that affect viral virulence and the reasons for its natural tropism for tumor cells are incompletely understood. By studying the effect of hypoxia on VV infection we found that vascular endothelial growth factor-A (VEGF) augments oncolytic VV cytotoxicity. VEGF derived from tumor cells acts to increase VV internalization resulting in increased replication and cytotoxicity in an AKT-dependent manner in both tumor cells and normal respiratory epithelial cells. Overexpression of VEGF also enhances VV infection within tumor tissue in vivo after systemic delivery. These results highlight the importance of VEGF expression in VV infection and have potential implications for the design of new strategies to prevent poxvirus infection and the development of future generations of oncolytic VV in combination with conventional or biological therapies.

Full-text

Available from: James R Tysome, Jun 18, 2014
0 Bookmarks
 · 
70 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Although we can treat cancers with cytotoxic chemotherapies, target them with molecules that inhibit oncogenic drivers, and induce substantial cell death with radiation, local and metastatic tumours recur, resulting in extensive morbidity and mortality. Indeed, driving a tumour to extinction is difficult. Geographically dispersed species of organisms are perhaps equally resistant to extinction, but >99.9% of species that have ever existed on this planet have become extinct. By contrast, we are nowhere near that level of success in cancer therapy. The phenomena are broadly analogous-in both cases, a genetically diverse population mutates and evolves through natural selection. The goal of cancer therapy is to cause cancer cell population extinction, or at least to limit any further increase in population size, to prevent the tumour burden from overwhelming the patient. However, despite available treatments, complete responses are rare, and partial responses are limited in duration. Many patients eventually relapse with tumours that evolve from cells that survive therapy. Similarly, species are remarkably resilient to environmental change. Paleontology can show us the conditions that lead to extinction and the characteristics of species that make them resistant to extinction. These lessons could be translated to improve cancer therapy and prognosis.
    Nature Reviews Clinical Oncology 02/2015; DOI:10.1038/nrclinonc.2015.12 · 15.03 Impact Factor